PRMT5 inhibitors and uses thereof
Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.
1. A compound of Formula:
or a pharmaceutically acceptable salt thereof,
wherein:
each R B is independently selected from the group consisting of hydrogen, 5-6 membered monocyclic heterocyclyl wherein said heterocyclyl has one ring heteroatom selected from nitrogen, oxygen and sulfur, and phenyl, each optionally substituted with 1, 2, 3, or 4 independent C 1-10 alkyl or halo;
each R y is independently selected from the group consisting of: a) phenyl optionally substituted with 1, 2, 3, or 4 independent C 1-10 alkyl or halo; b) —N(R B ) 2 ; and c) —C(O)N(R B ) 2 ;
m is 0, 1, 2, 3, or 4;
and
n is 0.
2. The compound of claim 1 , wherein m is 0, 1, or 2.
3. The compound of claim 1 , wherein the compound is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.
4. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
5. A kit or packaged pharmaceutical comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof, and instructions for use thereof.
6. The compound of claim 1 :
or a pharmaceutically acceptable salt thereof.
7. A compound selected from
and pharmaceutically acceptable salts thereof.